Selleck Chemicals supplies over 3,000 inhibitors used in the study of cell signaling pathways. We actively tracks the latest science so our customers can rely on us to be the leading supplier of the newest inhibitors.
Company WebsiteLRRK2-IN-1 is a potent and selective LRRK2 inhibitor with IC50 of 6 nM and 13 nM for LRRK2 (G2019S) and LRRK2 (WT), respectively.
More Information Supplier PageLRRK2-IN-1 is a potent and selective LRRK2 inhibitor with IC50 of 6 nM and 13 nM for LRRK2 (G2019S) and LRRK2 (WT), respectively.
More Information Supplier PageLSKL, Inhibitor of Thrombospondin (TSP-1), a small molecular peptide and competitive antagonist for transforming growth factor-β1 (TGF-β1), protects against subarachnoid fibrosis and hydrocephalus after subarachnoid hemorrhage (SAH).
More Information Supplier PageLSKL, Inhibitor of Thrombospondin (TSP-1), a small molecular peptide and competitive antagonist for transforming growth factor-β1 (TGF-β1), protects against subarachnoid fibrosis and hydrocephalus after subarachnoid hemorrhage (SAH).
More Information Supplier PageLTI-291 is the first small-molecule activator of Glucocerebrosidase(GCase) for the treatment of parkinson’s disease.
More Information Supplier PageLTI-291 is the first small-molecule activator of Glucocerebrosidase(GCase) for the treatment of parkinson’s disease.
More Information Supplier PageLTI-291 is the first small-molecule activator of Glucocerebrosidase(GCase) for the treatment of parkinson’s disease.
More Information Supplier PageLTI-291 is the first small-molecule activator of Glucocerebrosidase(GCase) for the treatment of parkinson’s disease.
More Information Supplier PageLTURM34 is a specific DNA-PK inhibitor, 170-fold more selective for DNA-PK activity compared to PI3K activity, with IC50 value of 0.034 μM.
More Information Supplier PageLTURM34 is a specific DNA-PK inhibitor, 170-fold more selective for DNA-PK activity compared to PI3K activity, with IC50 value of 0.034 μM.
More Information Supplier PageLu-135252 (Darusentan,HMR-4005) is a selective endothelin A receptor (ET-A receptor) antagonist indicated for the oral treatment of resistant hypertension.
More Information Supplier PageLu-135252 (Darusentan,HMR-4005) is a selective endothelin A receptor (ET-A receptor) antagonist indicated for the oral treatment of resistant hypertension.
More Information Supplier PageLubiprostone (RU 0211,SPI-0211) is an activator of ClC-2 chloride channels, used in the management of idiopathic chronic constipation.
More Information Supplier PageLucanthone is a novel autophagic inhibitor and also an orally available thioxanthone-based DNA intercalator and inhibitor of the DNA repair enzyme apurinic-apyrimidinic endonuclease 1.
More Information Supplier PageLucanthone is a novel autophagic inhibitor and also an orally available thioxanthone-based DNA intercalator and inhibitor of the DNA repair enzyme apurinic-apyrimidinic endonuclease 1.
More Information Supplier PageLucatumumab (Anti-TNFRSF5 / CD40) is a fully human antagonist monoclonal antibody, targeting CD40. It exhibits clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research. MW :150 KD.
More Information Supplier PageLucatumumab (Anti-TNFRSF5 / CD40) is a fully human antagonist monoclonal antibody, targeting CD40. It exhibits clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research. MW :150 KD.
More Information Supplier PageLucatumumab (Anti-TNFRSF5 / CD40) is a fully human antagonist monoclonal antibody, targeting CD40. It exhibits clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research. MW :150 KD.
More Information Supplier PageLucigenin (NSC-151912, L-6868) is a fluoerscent probe that exhibits a bluish-green fluorescence in the presence of endogenously generated superoxide anion radicals and chloride in cells.
More Information Supplier PageLucitanib (E-3810, AL3810) hydrochloride is a dual inhibitor of Vascular endothelial growth factor receptor (VEGFR) and Fibroblast growth factor receptor (FGFR). Lucitanib hydrochloride (E-3810, AL3810) potently and selectively inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1 and FGFR2 with IC50 of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively.
More Information Supplier PageLucitanib (E-3810, AL3810) hydrochloride is a dual inhibitor of Vascular endothelial growth factor receptor (VEGFR) and Fibroblast growth factor receptor (FGFR). Lucitanib hydrochloride (E-3810, AL3810) potently and selectively inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1 and FGFR2 with IC50 of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively.
More Information Supplier PageLuffa Cylindrica Stem Extract is extracted from the stem of Luffa aegyptiaca Miller.
More Information Supplier PagePF-07304814 is a phosphate prodrug of PF-00835231 that binds and inhibits SARS-CoV-2 3CLpro activity with a Ki of 174 nM.
More Information Supplier PagePF-07304814 is a phosphate prodrug of PF-00835231 that binds and inhibits SARS-CoV-2 3CLpro activity with a Ki of 174 nM.
More Information Supplier PageLumacaftor (VX-809, VRT 826809) acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM in fisher rat thyroid cells. Phase 3.
More Information Supplier PageLumacaftor (VX-809, VRT 826809) acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM in fisher rat thyroid cells. Phase 3.
More Information Supplier PageLumacaftor (VX-809, VRT 826809) acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM in fisher rat thyroid cells. Phase 3.
More Information Supplier PageLumacaftor (VX-809, VRT 826809) acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM in fisher rat thyroid cells. Phase 3.
More Information Supplier PageLumateperone (ITI-007) is an antagonist of 5-HT2A receptor with Ki of 0.54 nM. It has anticancer activity and can also be used in studies of psychiatric disorders such as schizophrenia.
More Information Supplier PageLumateperone (ITI-007) is an antagonist of 5-HT2A receptor with Ki of 0.54 nM. It has anticancer activity and can also be used in studies of psychiatric disorders such as schizophrenia.
More Information Supplier PageLumefantrine (benflumetol) is an antimalarial agent used to treat acute uncomplicated malaria.
More Information Supplier PageLumiliximab (Anti-FceR2 / CD23) is a monoclonal antibody targeting CD23, that inhibits allergen-induced responses. MW: 145.5 KD.
More Information Supplier PageLumiliximab (Anti-FceR2 / CD23) is a monoclonal antibody targeting CD23, that inhibits allergen-induced responses. MW: 145.5 KD.
More Information Supplier PageLumiliximab (Anti-FceR2 / CD23) is a monoclonal antibody targeting CD23, that inhibits allergen-induced responses. MW: 145.5 KD.
More Information Supplier PageLuminespib (AUY-922, NVP-AUY922, VER-52296) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Luminespib (AUY-922, NVP-AUY922) effectively downregulates and destabilizes the IGF-1Rβ protein and results in growth […]
More Information Supplier PageLuminespib (AUY-922, NVP-AUY922, VER-52296) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Luminespib (AUY-922, NVP-AUY922) effectively downregulates and destabilizes the IGF-1Rβ protein and results in growth […]
More Information Supplier PageLuminespib (AUY-922, NVP-AUY922, VER-52296) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Luminespib (AUY-922, NVP-AUY922) effectively downregulates and destabilizes the IGF-1Rβ protein and results in growth […]
More Information Supplier PageLuminespib (AUY-922, NVP-AUY922, VER-52296) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Luminespib (AUY-922, NVP-AUY922) effectively downregulates and destabilizes the IGF-1Rβ protein and results in growth […]
More Information Supplier Page
Luminol (Diogenes reagent, 3-Aminophthalhydrazide) is a versatile chemical exhibiting chemiluminescence with a blue glow, when mixed with an appropriate oxidizing agent. Luminol is uesed in forensic investigations to detect trace amounts of blood at crime scenes and in biological researches to detect copper, iron, and cyanides, as well as specific proteins by western blot. Luminol […]
More Information Supplier Page
Lumiracoxib (COX-189) is a novel, selective COX-2 inhibitor with Ki of 0.06 μM. It also inhibits COX1 with Ki of 3 μM.
More Information Supplier PageLumretuzumab (Anti-ERBB3 / HER3) is an immunoconjugate containing a glycoengineered, humanized monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3) with potential antineoplastic activity. MW: 147.16 KD.
More Information Supplier PageLumretuzumab (Anti-ERBB3 / HER3) is an immunoconjugate containing a glycoengineered, humanized monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3) with potential antineoplastic activity. MW: 147.16 KD.
More Information Supplier PageLumretuzumab (Anti-ERBB3 / HER3) is an immunoconjugate containing a glycoengineered, humanized monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3) with potential antineoplastic activity. MW: 147.16 KD.
More Information Supplier PageLupartumab (Anti-LYPD3 / C4.4A) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of the antibody-drug conjugate Lupartumab Amadotin. MW: 145.5 kD.
More Information Supplier PageLupartumab (Anti-LYPD3 / C4.4A) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of the antibody-drug conjugate Lupartumab Amadotin. MW: 145.5 kD.
More Information Supplier PageLupartumab (Anti-LYPD3 / C4.4A) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of the antibody-drug conjugate Lupartumab Amadotin. MW: 145.5 kD.
More Information Supplier PageLupenone (Lup-20(29)-en-3-one, lupeone) is an isolated compound exhibiting anti-oxidative, anti-inflammation, and anti-diabetic activities. Lupenone can protect SH-SY5y cells against METH-induced neuronal apoptosis through the PI3K/Akt pathway.
More Information Supplier PageLupeol (Clerodol, Monogynol B, Fagarasterol, Farganasterol) is a significant lupane-type triterpene represented in the plant, fungi and animal kingdoms with anticancer, antiprotozoal, chemopreventive and anti-inflammatory properties.
More Information Supplier Page
